Northwest Wealth Management LLC Has $522,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Northwest Wealth Management LLC increased its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 30.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 895 shares of the company’s stock after purchasing an additional 211 shares during the period. Northwest Wealth Management LLC’s holdings in Eli Lilly and Company were worth $522,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $29,000. Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $37,000. Finally, Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth $36,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE LLY traded down $5.10 during trading on Tuesday, hitting $859.90. The stock had a trading volume of 1,787,329 shares, compared to its average volume of 2,946,184. The company has a market capitalization of $817.26 billion, a PE ratio of 127.46, a PEG ratio of 1.85 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $882.14. The firm has a fifty day moving average of $777.92 and a two-hundred day moving average of $711.44.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the business posted $1.62 EPS. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Thursday, May 16th were given a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.60%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 192,794 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $829.77, for a total value of $159,974,677.38. Following the transaction, the insider now directly owns 98,208,810 shares in the company, valued at approximately $81,490,724,273.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 192,794 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $829.77, for a total value of $159,974,677.38. Following the completion of the sale, the insider now directly owns 98,208,810 shares of the company’s stock, valued at approximately $81,490,724,273.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 477,294 shares of company stock valued at $397,122,216. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Jefferies Financial Group upped their target price on Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a report on Friday. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $787.53.

Read Our Latest Stock Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.